High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity

Brachytherapy

Volumn 14, Issue 5, 2015, Pages 670-676

  Bece, Andrej ^a,b   Patanjali, Nitya ^a,b   Jackson, Michael ^c   Whitaker, May ^a,b   Hruby, George ^a,b,d  

^a Chris O'Brien Lifehouse ^*  (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Brachytherapy; Genitourinary toxicity; High dose rate; Prostate cancer; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER SPASM; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CANCER PATIENT; EXTERNAL BEAM RADIOTHERAPY; GENITOURINARY TOXICITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INDWELLING CATHETER; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEUROGENIC BLADDER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SUPRAPUBIC CATHETER; TREATMENT OUTCOME; URETHRA STENOSIS; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT OBSTRUCTION; ADVERSE EFFECTS; BLOOD; CONSTRICTION, PATHOLOGIC; FOLLOW UP; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; URINARY TRACT;

PROSTATE SPECIFIC ANTIGEN;

AGED; BRACHYTHERAPY; CONSTRICTION, PATHOLOGIC; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; URINARY TRACT;

EID: 84940453444     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2015.04.004     Document Type: Article

References (29)

1. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson Randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
2. Fowler J.F., Toma-Dasu I., Dasu A. Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?. Anticancer Res 2013, 33:1009-1011.
3. Hoskin P.J., Rojas A.M., Bownes P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103:217-222.
4. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
5. Khor R., Duchesne G., Tai K.H., et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:679-685.
6. Spratt D.E., Zumsteg Z.S., Ghadjar P., et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 2014, 114:360-367.
7. Sullivan L., Williams S.G., Tai K.H., et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009, 91:232-236.
8. Morton G., Loblaw A., Cheung P., et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiother Oncol 2011, 100:463-467.
9. Hindson B.R., Millar J.L., Matheson B. Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors. Brachytherapy 2013, 12:50-55.
10. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
11. Whalley D., Patanjali N., Jackson M., et al. HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre. J Med Imaging Radiat Oncol 2012, 56:220-226.
12. Hruby G., Chen J.Y., Bucci J., et al. Patients' experiences of high-dose-rate brachytherapy boost for prostate cancer using an inpatient protocol. Brachytherapy 2011, 10:395-400.
13. Chen J.Y., Hruby G., Stockler M.R., et al. Patient-reported outcomes of prostate high-dose-rate brachytherapy boost comparing an outpatient and inpatient protocol: A two-center chronologic cohort study. Brachytherapy 2011, 10:454-460.
14. Galalae R.M., Martinez A., Nuernberg N., et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?. Strahlenther Onkol 2006, 182:135-141.
15. Whitaker M., Hruby G., Lovett A., Patanjali N. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 2011, 101:490-494.
16. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
17. Zaorsky N.G., Doyle L.A., Yamoah K., et al. High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treat Rev 2014, 40:414-425.
18. Kaprealian T., Weinberg V., Speight J.L., et al. High-dose-rate brachytherapy boost for prostate cancer: Comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys 2012, 82:222-227.
19. Prada P.J., González H., Fernández J., et al. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 Years of experience. BJU Int 2012, 109:1787-1793.
20. Hsu I.-C., Bae K., Shinohara K., et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010, 78:751-758.
21. Mohammed N., Kestin L., Ghilezan M., et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:204-212.
22. Jarosek S.L., Virnig B.A., Chu H., Elliott S.P. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol 2014, 67:273-280.
23. Merrick G.S., Butler W.M., Wallner K.E., et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol 2006, 175:1376-1381.
24. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002, 52:461-468.
25. Earley J.J., Abdelbaky A.M., Cunningham M.J., et al. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: A matched case-control study. Radiother Oncol 2012, 104:187-191.
26. McLaughlin P., Evans C., Feng M., et al. Radiographic, anatomic, and developmental basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys 2009, 76:369-e378.
27. McLaughlin P.W., Narayana V. High-dose-rate strictures: A theory of cancer meets anatomic reality. Brachytherapy 2013, 12:199-201.
28. Hoskin P.J., Bownes P.J., Ostler P., et al. High dose rate afterloading brachytherapy for prostate cancer: Catheter and gland movement between fractions. Radiother Oncol 2003, 68:285-288.
29. Simnor T., Li S., Lowe G., et al. Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol 2009, 93:253-258.